Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
MYNZ is expected to report earnings to rise 45.45% to -640 cents per share on April 01
Q4'24
Est.
$-6.40
Q3'24
Missed
by $4.27
Q2'24
Missed
by $19.45
Q1'24
Est.
$-0.25
Q4'23
Beat
by $0.01
The last earnings report on October 30 showed earnings per share of -440 cents, missing the estimate of -12 cents. With 40.25K shares outstanding, the current market capitalization sits at 20.77M.